Developer docs
API playgroundTry for free, no card

Search company profiles

RSP Systems

Full company profile

uuid0002fg9

Namestring
RSP Systems
Legal namestring
RSP Systems A/S
Websiteurl
rspsystems.com
Company typeenum
Private
Founded yearint
2006
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOdense, Denmark
HQ citystring
Odense
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
non-invasive glucose monitoring, Raman spectroscopy devices, continuous glucose monitoring, diabetes diagnostic technology, medical device development
Industry4 codes
PRIMARYHLAHAHAA
Continuous Glucose Monitoring (CGM) Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHACAL
Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLAHAHAG
Blood Glucose Monitoring (BGM) Meters & Test Strips
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYCRACAQAE
Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Non-Invasive Glucose Monitoring
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Non-invasive Glucose Monitoring Devices
TypeHardware Sales
Description

Future revenue stream from sales of the GlucoBeam Smart non-invasive glucose monitoring device. The device is currently investigational and not yet approved for commercial use. Revenue model likely to include device sales combined with subscription-based software/algorithm updates.

rspsystems.com
2Technology Licensing and Partnership
TypeLicensing Royalties
Description

Potential revenue from licensing proprietary Raman spectroscopy technology, algorithms, and calibration methods to other medical device manufacturers. Company offers consulting services for companies seeking to develop non-invasive solutions.

rspsystems.com
3Algorithm and Software Services
TypeSubscription Recurring
Description

Revenue from algorithm development and software deployment services as part of their non-invasive solutions offering. Phase 2-4 services include data model design, clinical trials, algorithm development, software design and deployment, and ongoing updates.

rspsystems.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1GlucoBeam Smart
Description

Non-invasive glucose monitoring device using Raman spectroscopy technology for pain-free blood glucose measurement

rspsystems.com
Core offering1 text field

RSP Systems develops and is commercializing the GlucoBeam Smart device, a non-invasive glucose monitor that uses Critical-depth Raman spectroscopy and proprietary multivariate regression algorithms to measure blood glucose levels painlessly from the interstitial fluid in the upper living layers of the skin, eliminating the need for finger pricks or implanted sensors. The company also offers a Non-Invasive Solutions Service providing concept development, device configuration, data model design, clinical trials, algorithm development, and software deployment to other organizations seeking to leverage Raman spectroscopy technology for additional analytes and form factors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 99.8% of measurements within A+B zones in consensus error grid (Type 2 diabetes subset, 15+ day home use study)
+4 more records
Product overview1 text field

RSP Systems offers a unified portfolio centered on the GlucoBeam Smart device — a non-invasive glucose monitoring product using proprietary Raman spectroscopy technology. The company also provides contract development services (Non-Invasive Solutions Service) for other organizations seeking to leverage RSP's spectroscopic platform for additional analytes and form factors. The technology is built on supervised machine learning algorithms trained with real-world data spanning clinical studies and home-use settings.

Product and service2 records
1GlucoBeam Smart
CategoryNon-Invasive Glucose Monitoring Device
Description

A non-invasive glucose monitoring device that uses Critical-depth Raman spectroscopy and proprietary multivariate regression algorithms to measure blood glucose levels painlessly from the upper living layers of the skin without needles or finger pricks. The device is intended for people with Type 1 and Type 2 diabetes and the pre-diabetes population who require regular glucose monitoring. GlucoBeam Smart is investigational and not yet approved for commercial use.

2Non-Invasive Solutions Service
CategoryContract Development and Technology Services
Description

A four-phase advisory and contract development service for medical device manufacturers and healthcare technology companies wanting to develop non-invasive monitoring devices using Raman spectroscopy technology. Services cover concept development, device configuration, data model design, clinical trials, algorithm development, software design, and deployment support. Target customers are companies seeking to leverage RSP's spectroscopic platform for additional analytes and form factors.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Institute for Diabetes Technology, University of Ulm, Germany
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-25
Description

Collaborated on Nature Scientific Reports publication (March 2025) covering pre-trained calibration models for non-invasive glucose monitoring. RSP Systems collaborated with Dr. Guido Freckmann and Eva Zschornack from the Institute, along with clinical advisor Professor K.D. Hepp.

rspsystems.com
2Steno Diabetes Center Copenhagen
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical study site for multiple RSP studies including RSP-17 (hypoglycemia range assessment) and RSP-24 (long-term calibration stability). Steno Diabetes Center is a leading Danish diabetes research and treatment center.

rspsystems.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical study site for RSP-10 (long-term calibration stability) and RSP-24 studies. Located at Odense University Hospital where RSP Systems conducted early feasibility studies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical study site for RSP-19 study evaluating laser polarization impact on device performance.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical study site for RSP-08 study comparing multiple validated glucose reference methods including microdialysis, capillary, and CGM systems.

6m&i-Fachklinik Bad Heilbrunn, Germany
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Site 1 for Glucobrunn study (RSP-09) conducted with 30 participants with Type 1 and Type 2 diabetes for calibration model establishment.

rspsystems.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

OneTouch blood glucose monitoring brand owned by Platinum Equity. Comparable incumbent in the BGM space whose customers RSP could address with non-invasive alternatives.

TypeBroad incumbent
Description

Manufacturer of CONTOUR blood glucose meters. Relevant incumbent peer in the diabetes monitoring space, particularly for the pre-diabetes and consumer health segments RSP targets.

TypeEmerging player
Description

Dutch company developing a tear-fluid-based continuous glucose sensor. Comparable as a European emerging glucose monitoring innovator using novel biomarker approaches.

TypeBroad incumbent
Description

Major diabetes care company with Accu-Chek blood glucose monitoring portfolio. Comparable as a large incumbent RSP would compete with or seek licensing partnership from.

TypeBroad incumbent
Description

Manufacturer of the FreeStyle Libre line of flash and continuous glucose monitors, the world's largest CGM by volume. Highly relevant as the dominant non-invasive-adjacent incumbent whose market RSP would target or partner with.

TypeDirect peer
Description

Developer of Eversense, an implantable long-term CGM. Closely comparable as a pre-commercial-to-commercial stage glucose monitoring company competing on durability and patient experience, both seeking differentiation from standard CGMs.

TypeBroad incumbent
Description

Market leader in continuous glucose monitoring with the G6 and G7 CGM systems, dominant in the U.S. and globally. Directly comparable as the incumbent RSP would either replace or partner with in the glucose monitoring space.

TypeDirect peer
Description

Berlin-based company developing non-invasive glucose monitoring using infrared spectroscopy/photothermal technology. Closely comparable as a European peer pursuing non-invasive glucose via optical/photonic methods.

TypeBroad incumbent
Description

Operates the Guardian CGM system integrated with insulin pumps (MiniMed). Comparable as a major incumbent in diabetes monitoring and a potential strategic acquirer of RSP's non-invasive technology.

10Integrity Applications (GlucoTrack)
TypeDirect peer
Description

Developer of GlucoTrack, a non-invasive glucose monitoring device using a combination of ultrasonic, electromagnetic, and thermal technologies. Direct peer in the non-invasive glucose device category.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RSP Systems

Non-Invasive Glucose Monitoringrspsystems.com

RSP Systems firmographics

Firmographics
Name
RSP Systems
Legal name
RSP Systems A/S
Website
https://rspsystems.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

RSP Systems industry classification

Industry
Product category
Non-Invasive Glucose Monitoring
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAHAA
Continuous Glucose Monitoring (CGM) Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHACAL
Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLAHAHAG
Blood Glucose Monitoring (BGM) Meters & Test Strips
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYCRACAQAE
Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)

Keywords

  • Non-invasive glucose monitoring
  • Raman spectroscopy devices
  • Continuous glucose monitoring
  • Diabetes diagnostic technology
  • Medical device development

Where RSP Systems is headquartered

Location

Headquarters

HQ city
Odense
HQ country
Denmark
HQ region
Europe

Offices2 records

Markets served

RSP Systems business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Non-invasive Glucose Monitoring Devices: Future revenue stream from sales of the GlucoBeam Smart non-invasive glucose monitoring device. The device is currently investigational and not yet approved for commercial use. Revenue model likely to include device sales combined with subscription-based software/algorithm updates.
  2. Technology Licensing and Partnership: Potential revenue from licensing proprietary Raman spectroscopy technology, algorithms, and calibration methods to other medical device manufacturers. Company offers consulting services for companies seeking to develop non-invasive solutions.
  3. Algorithm and Software Services: Revenue from algorithm development and software deployment services as part of their non-invasive solutions offering. Phase 2-4 services include data model design, clinical trials, algorithm development, software design and deployment, and ongoing updates.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

RSP Systems product offering

Product offering

Core offering

RSP Systems develops and is commercializing the GlucoBeam Smart device, a non-invasive glucose monitor that uses Critical-depth Raman spectroscopy and proprietary multivariate regression algorithms to measure blood glucose levels painlessly from the interstitial fluid in the upper living layers of the skin, eliminating the need for finger pricks or implanted sensors. The company also offers a Non-Invasive Solutions Service providing concept development, device configuration, data model design, clinical trials, algorithm development, and software deployment to other organizations seeking to leverage Raman spectroscopy technology for additional analytes and form factors.

Product overview

RSP Systems offers a unified portfolio centered on the GlucoBeam Smart device — a non-invasive glucose monitoring product using proprietary Raman spectroscopy technology. The company also provides contract development services (Non-Invasive Solutions Service) for other organizations seeking to leverage RSP's spectroscopic platform for additional analytes and form factors. The technology is built on supervised machine learning algorithms trained with real-world data spanning clinical studies and home-use settings.

Differentiator

Problem solved

Functional benefit

Brands

  • GlucoBeam Smart: Non-invasive glucose monitoring device using Raman spectroscopy technology for pain-free blood glucose measurement

Products and services

  • GlucoBeam Smart A non-invasive glucose monitoring device that uses Critical-depth Raman spectroscopy and proprietary multivariate regression algorithms to measure blood glucose levels painlessly from the upper living layers of the skin without needles or finger pricks. The device is intended for people with Type 1 and Type 2 diabetes and the pre-diabetes population who require regular glucose monitoring. GlucoBeam Smart is investigational and not yet approved for commercial use.
  • Non-Invasive Solutions Service A four-phase advisory and contract development service for medical device manufacturers and healthcare technology companies wanting to develop non-invasive monitoring devices using Raman spectroscopy technology. Services cover concept development, device configuration, data model design, clinical trials, algorithm development, software design, and deployment support. Target customers are companies seeking to leverage RSP's spectroscopic platform for additional analytes and form factors.

Quantifiable outcome

  • 99.8% of measurements within A+B zones in consensus error grid (Type 2 diabetes subset, 15+ day home use study)
  • +4 more outcomes

Companies that use RSP Systems

Customer profile

Segments3 records

Ideal customer profiles3 records

RSP Systems technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

RSP Systems partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Institute for Diabetes Technology, University of Ulm, GermanycoreStrategic or Co-development Partner · 25 March 2025Collaborated on Nature Scientific Reports publication (March 2025) covering pre-trained calibration models for non-invasive glucose monitoring. RSP Systems collaborated with Dr. Guido Freckmann and Eva Zschornack from the Institute, along with clinical advisor Professor K.D. Hepp.
  • Steno Diabetes Center CopenhagencoreStrategic or Co-development PartnerClinical study site for multiple RSP studies including RSP-17 (hypoglycemia range assessment) and RSP-24 (long-term calibration stability). Steno Diabetes Center is a leading Danish diabetes research and treatment center.
  • Steno Diabetes Center OdensecoreStrategic or Co-development PartnerClinical study site for RSP-10 (long-term calibration stability) and RSP-24 studies. Located at Odense University Hospital where RSP Systems conducted early feasibility studies.
  • Steno Diabetes Center AarhuscoreStrategic or Co-development PartnerClinical study site for RSP-19 study evaluating laser polarization impact on device performance.
  • Sahlgrenska University Hospital, SwedencoreStrategic or Co-development PartnerClinical study site for RSP-08 study comparing multiple validated glucose reference methods including microdialysis, capillary, and CGM systems.
  • m&i-Fachklinik Bad Heilbrunn, GermanyminorStrategic or Co-development PartnerSite 1 for Glucobrunn study (RSP-09) conducted with 30 participants with Type 1 and Type 2 diabetes for calibration model establishment.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

RSP Systems competitors and assessment

Company assessment

Broad incumbents

  • LifeScan (OneTouch): OneTouch blood glucose monitoring brand owned by Platinum Equity. Comparable incumbent in the BGM space whose customers RSP could address with non-invasive alternatives.
  • Ascensia Diabetes Care: Manufacturer of CONTOUR blood glucose meters. Relevant incumbent peer in the diabetes monitoring space, particularly for the pre-diabetes and consumer health segments RSP targets.
  • Roche Diabetes Care: Major diabetes care company with Accu-Chek blood glucose monitoring portfolio. Comparable as a large incumbent RSP would compete with or seek licensing partnership from.
  • Abbott Diabetes Care: Manufacturer of the FreeStyle Libre line of flash and continuous glucose monitors, the world's largest CGM by volume. Highly relevant as the dominant non-invasive-adjacent incumbent whose market RSP would target or partner with.
  • Dexcom: Market leader in continuous glucose monitoring with the G6 and G7 CGM systems, dominant in the U.S. and globally. Directly comparable as the incumbent RSP would either replace or partner with in the glucose monitoring space.
  • Medtronic Diabetes: Operates the Guardian CGM system integrated with insulin pumps (MiniMed). Comparable as a major incumbent in diabetes monitoring and a potential strategic acquirer of RSP's non-invasive technology.

Emerging players

  • NovioSense: Dutch company developing a tear-fluid-based continuous glucose sensor. Comparable as a European emerging glucose monitoring innovator using novel biomarker approaches.

Direct peers

  • Senseonics Holdings: Developer of Eversense, an implantable long-term CGM. Closely comparable as a pre-commercial-to-commercial stage glucose monitoring company competing on durability and patient experience, both seeking differentiation from standard CGMs.
  • DiaMonTech: Berlin-based company developing non-invasive glucose monitoring using infrared spectroscopy/photothermal technology. Closely comparable as a European peer pursuing non-invasive glucose via optical/photonic methods.
  • Integrity Applications (GlucoTrack): Developer of GlucoTrack, a non-invasive glucose monitoring device using a combination of ultrasonic, electromagnetic, and thermal technologies. Direct peer in the non-invasive glucose device category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

RSP Systems social profiles

Digital presence

RSP Systems compliance and trust

Trust signal

Compliance4 records

RSP Systems financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RSP Systems leadership team

Management profile

Number of profiles

Profiles8 records

RSP Systems funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RSP Systems M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RSP Systems

What does RSP Systems do?

RSP Systems develops and is commercializing the GlucoBeam Smart device, a non-invasive glucose monitor that uses Critical-depth Raman spectroscopy and proprietary multivariate regression algorithms to measure blood glucose levels painlessly from the interstitial fluid in the upper living layers of the skin, eliminating the need for finger pricks or implanted sensors. The company also offers a Non-Invasive Solutions Service providing concept development, device configuration, data model design, clinical trials, algorithm development, and software deployment to other organizations seeking to leverage Raman spectroscopy technology for additional analytes and form factors.

Is RSP Systems a public or private company?

RSP Systems is a private company. It is classified as venture growth investor backed and is currently operating.

When was RSP Systems founded?

RSP Systems was founded in 2006. It employs 11 to 50 people.

Where is RSP Systems based?

RSP Systems is headquartered in Odense, Denmark, in the Europe region.

How does RSP Systems make money?

Three revenue lines are on record. Non-invasive Glucose Monitoring Devices are the primary driver. The others are technology Licensing and Partnership and algorithm and Software Services.

Who are RSP Systems's main competitors?

Broad incumbents on record are LifeScan (OneTouch), Ascensia Diabetes Care, Roche Diabetes Care, Abbott Diabetes Care, Dexcom and Medtronic Diabetes. NovioSense is listed as an emerging player. Direct peers are Senseonics Holdings, DiaMonTech and Integrity Applications (GlucoTrack).

Does RSP Systems have an API?

No public API is recorded for RSP Systems.

What industry is RSP Systems in?

RSP Systems's product category is Non-Invasive Glucose Monitoring. Its primary akta.pro industry code is HLAHAHAA, Continuous Glucose Monitoring (CGM) Systems, with a secondary code of HLAHACAL, Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals